300199 翰宇药业
已收盘 06-05 15:00:00
资讯
新帖
简况
翰宇药业最新公告：卡贝缩宫素原料药获欧盟DCP核准
证券之星 · 06-01
翰宇药业最新公告：卡贝缩宫素原料药获欧盟DCP核准
翰宇药业（300199）披露2025年年度股东会决议公告，5月21日股价下跌3.19%
证券之星 · 05-21
翰宇药业（300199）披露2025年年度股东会决议公告，5月21日股价下跌3.19%
翰宇药业最新公告：签订多肽原料药销售合作框架协议拟定销售金额不低于3.27亿元
证券之星 · 05-19
翰宇药业最新公告：签订多肽原料药销售合作框架协议拟定销售金额不低于3.27亿元
翰宇药业最新公告：卡贝缩宫素注射液获印度尼西亚上市许可
证券之星 · 05-14
翰宇药业最新公告：卡贝缩宫素注射液获印度尼西亚上市许可
翰宇药业：公司财务核算工作严格遵循《企业会计准则》及公司会计政策
证券之星 · 05-12
翰宇药业：公司财务核算工作严格遵循《企业会计准则》及公司会计政策
翰宇药业（300199）披露司美格鲁肽注射液取得III期临床试验数据的公告，5月6日股价上涨0.82%
证券之星 · 05-06
翰宇药业（300199）披露司美格鲁肽注射液取得III期临床试验数据的公告，5月6日股价上涨0.82%
翰宇药业(300199.SZ)：司美格鲁肽注射液减重及降糖两项国内适应症的III期临床试验均获得达到等效标准
智通财经 · 05-06
翰宇药业(300199.SZ)：司美格鲁肽注射液减重及降糖两项国内适应症的III期临床试验均获得达到等效标准
每周股票复盘：翰宇药业（300199）2025年营收增长63.73%
证券之星 · 05-03
每周股票复盘：翰宇药业（300199）2025年营收增长63.73%
翰宇药业（300199）2026年一季报简析：净利润同比增长82.94%，短期债务压力上升
证券之星 · 04-30
翰宇药业（300199）2026年一季报简析：净利润同比增长82.94%，短期债务压力上升
图解翰宇药业一季报：第一季度单季净利润同比增长82.94%
证券之星 · 04-29
图解翰宇药业一季报：第一季度单季净利润同比增长82.94%
翰宇药业（300199）披露控股股东部分股票质押暨解除质押公告，4月15日股价下跌1.27%
证券之星 · 04-15
翰宇药业（300199）披露控股股东部分股票质押暨解除质押公告，4月15日股价下跌1.27%
翰宇药业（300199）披露2026年第二次临时股东会决议公告，3月17日股价上涨1.16%
证券之星 · 03-17
翰宇药业（300199）披露2026年第二次临时股东会决议公告，3月17日股价上涨1.16%
政旦志远会计所2025年收入破亿
YCY会计行业观察 · 02-28
政旦志远会计所2025年收入破亿
翰宇药业：公司已通过前瞻性布局产能扩张、持续完善质量体系与全球合规认证
证券之星 · 02-27
翰宇药业：公司已通过前瞻性布局产能扩张、持续完善质量体系与全球合规认证
翰宇药业（300199）披露召开2026年第二次临时股东会的通知，2月25日股价上涨2.63%
证券之星 · 02-25
翰宇药业（300199）披露召开2026年第二次临时股东会的通知，2月25日股价上涨2.63%
翰宇药业：预计2025年归母净利润扭亏为盈
证券之星 · 02-25
翰宇药业：预计2025年归母净利润扭亏为盈
翰宇药业（300199）披露醋酸格拉替雷注射液获美国FDA批准证书，2月24日股价下跌0.44%
证券之星 · 02-24
翰宇药业（300199）披露醋酸格拉替雷注射液获美国FDA批准证书，2月24日股价下跌0.44%
翰宇药业(300199.SZ)：醋酸格拉替雷注射液获得美国FDA批准证书
智通财经 · 02-12
翰宇药业(300199.SZ)：醋酸格拉替雷注射液获得美国FDA批准证书
翰宇药业最新公告：2025年预盈4000万元–5000万元GLP-1制剂与原料药业务规模大幅放量
证券之星 · 01-28
翰宇药业最新公告：2025年预盈4000万元–5000万元GLP-1制剂与原料药业务规模大幅放量
中国药企拿下诺和诺德订单？涉1.8亿元GLP-1原料药
健识局 · 01-19
中国药企拿下诺和诺德订单？涉1.8亿元GLP-1原料药
加载更多
公司概况
公司名称：
深圳翰宇药业股份有限公司
所属行业：
医药制造业
上市日期：
2011-04-07
主营业务：
深圳翰宇药业股份有限公司的主营业务是多肽制剂、原料药、小核酸与CRDMO的研发、销售。公司的主要产品是多肽制剂、原料药、小核酸与CRDMO。
发行价格：
30.19
{"stockData":{"symbol":"300199","market":"SZ","secType":"STK","nameCN":"翰宇药业","latestPrice":21.47,"timestamp":1780642995000,"preClose":22.86,"halted":0,"volume":57355246,"delay":0,"changeRate":-0.0608,"floatShares":745000000,"shares":883000000,"eps":0.1071,"marketStatus":"已收盘","change":-1.39,"latestTime":"06-05 15:00:00","open":23.4,"high":23.49,"low":21.36,"amount":1266000000,"amplitude":0.0932,"askPrice":21.48,"askSize":634,"bidPrice":21.47,"bidSize":405,"shortable":0,"etf":0,"ttmEps":0.1071,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780882200000},"marketStatusCode":5,"adr":0,"adjPreClose":22.86,"symbolType":"stock","openAndCloseTimeList":[[1780623000000,1780630200000],[1780635600000,1780642800000]],"highLimit":25.15,"lowLimit":20.57,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":883241336,"isCdr":false,"pbRate":27.23,"roa":"--","peRate":200.466853,"roe":"18.86%","epsLYR":0.04,"committee":-0.277778,"marketValue":18963000000,"turnoverRate":0.077,"status":1,"floatMarketCap":15999000000},"requestUrl":"/m/hq/s/300199","defaultTab":"news","newsList":[{"id":"2640244958","title":"翰宇药业最新公告：卡贝缩宫素原料药获欧盟DCP核准","url":"https://stock-news.laohu8.com/highlight/detail?id=2640244958","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640244958?lang=zh_cn&edition=full","pubTime":"2026-06-01 18:10","pubTimestamp":1780308636,"startTime":"0","endTime":"0","summary":"翰宇药业(300199.SZ)公告称，公司收到欧盟DCP核准文件，卡贝缩宫素原料药获欧盟分散审批程序核准，有助于拓宽海外市场，提升在欧盟及全球妇产科用药领域的竞争地位。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100029162.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","FESXmain","BK0070","BK0239","BK0028","FSXEmain","300199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637819903","title":"翰宇药业（300199）披露2025年年度股东会决议公告，5月21日股价下跌3.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637819903","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637819903?lang=zh_cn&edition=full","pubTime":"2026-05-21 17:47","pubTimestamp":1779356861,"startTime":"0","endTime":"0","summary":"截至2026年5月21日收盘，翰宇药业报收于22.75元，较前一交易日下跌3.19%，最新总市值为200.94亿元。该股当日开盘23.55元，最高24.0元，最低22.68元，成交额达10.71亿元，换手率为6.15%。公司于近日披露《2025年年度股东会决议公告》。公告显示，深圳翰宇药业股份有限公司于2026年5月20日召开2025年年度股东会，会议由董事会召集，采用现场与网络投票相结合方式举行。出席会议股东共363人，代表股份193,488,015股，占公司有表决权股份总数的21.9066%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100032976.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0077","BK0239","BK0188","300199","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636858137","title":"翰宇药业最新公告：签订多肽原料药销售合作框架协议拟定销售金额不低于3.27亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2636858137","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636858137?lang=zh_cn&edition=full","pubTime":"2026-05-19 19:00","pubTimestamp":1779188409,"startTime":"0","endTime":"0","summary":"翰宇药业(300199.SZ)公告称，为拓宽海外业务布局、加快推进GLP-1原料药的商业化进程，公司与合作方于5月18日在深圳签署了多肽原料药销售合作框架协议，拟定销售金额不低于人民币3.27亿元，占公司最近一期经审计营业收入的33.84%。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900035862.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199","BK0070","BK0188","BK0239","BK0077","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635790736","title":"翰宇药业最新公告：卡贝缩宫素注射液获印度尼西亚上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2635790736","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635790736?lang=zh_cn&edition=full","pubTime":"2026-05-14 17:33","pubTimestamp":1778751227,"startTime":"0","endTime":"0","summary":"翰宇药业(300199.SZ)公告称，公司收到印度尼西亚国家药品食品监督管理局颁发的卡贝缩宫素注射液上市许可批准。该药物为新一代强效宫缩剂，用于降低产后出血发生率，作用强度是缩宫素的10倍。此次获批有助于公司拓展海外市场，提升在东南亚及全球妇产科用药领域的竞争力。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400030720.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0077","BK0028","300199","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634148702","title":"翰宇药业：公司财务核算工作严格遵循《企业会计准则》及公司会计政策","url":"https://stock-news.laohu8.com/highlight/detail?id=2634148702","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634148702?lang=zh_cn&edition=full","pubTime":"2026-05-12 20:52","pubTimestamp":1778590328,"startTime":"0","endTime":"0","summary":"关于您提到的营业收入变化率与销售费用、管理费用变化率存在差异的问题，公司2025年度营业收入同比增长较快，主要得益于国际制剂及原料药业务的放量增长。公司财务核算工作严格遵循《企业会计准则》及公司会计政策，费用确认均按照权责发生制规范核算，不存在虚假等情形。公司年度财务报告已经审计，真实、准确、完整地反映了公司的财务状况和经营成果。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051200038109.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","BK0188","300199","BK0070","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633131514","title":"翰宇药业（300199）披露司美格鲁肽注射液取得III期临床试验数据的公告，5月6日股价上涨0.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633131514","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633131514?lang=zh_cn&edition=full","pubTime":"2026-05-06 22:04","pubTimestamp":1778076263,"startTime":"0","endTime":"0","summary":"截至2026年5月6日收盘，翰宇药业报收于20.91元，较前一交易日上涨0.82%，最新总市值为184.69亿元。近日，深圳翰宇药业股份有限公司发布《关于司美格鲁肽注射液取得III期临床试验数据的公告》。公告显示，公司司美格鲁肽注射液III期临床试验取得积极结果，降糖及减重两项适应症均达到等效标准。药物安全性良好，未发生严重不良反应。公司已获得III期临床试验报告，将启动上市许可申请工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600039535.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300199","BK0188","BK0077","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633182090","title":"翰宇药业(300199.SZ)：司美格鲁肽注射液减重及降糖两项国内适应症的III期临床试验均获得达到等效标准","url":"https://stock-news.laohu8.com/highlight/detail?id=2633182090","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633182090?lang=zh_cn&edition=full","pubTime":"2026-05-06 19:13","pubTimestamp":1778065991,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业(300199.SZ)发布公告，近日，公司司美格鲁肽注射液取得了III期临床数据，数据显示，该药物的减重及降糖两项国内适应症的III期临床试验均获得了达到等效标准。公司司美格鲁肽注射液在国内进行了两项临床试验，分别是：一项在二甲双胍单药治疗血糖控制不佳的2型糖尿病患者中比较HY310注射液与诺和泰®治疗32周的疗效和安全性的多中心、随机、开放设计的III期临床研究。一项在肥胖患者中比较HY310注射液与诺和盈®治疗44周的疗效和安全性的多中心、随机、开放设计的III期临床研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438679.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","300199","BK0239","BK0077","BK0028","BK0070","BK4134","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632167906","title":"每周股票复盘：翰宇药业（300199）2025年营收增长63.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632167906","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632167906?lang=zh_cn&edition=full","pubTime":"2026-05-03 01:15","pubTimestamp":1777742112,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，翰宇药业报收于20.74元，较上周的21.74元下跌4.6%。本周关注点来自业绩披露要点：翰宇药业2025年主营收入9.66亿元，同比上升63.73%。股本股东变化股东户数变动截至2026年3月31日，翰宇药业股东户数为9.88万户，较2025年12月31日减少2454.0户，减幅2.42%。业绩披露要点财务报告翰宇药业2025年年报显示，主营收入9.66亿元，同比上升63.73%；归母净利润3656.99万元，同比上升121.06%；扣非净利润1380.66万元，同比上升105.76%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300000083.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631891578","title":"翰宇药业（300199）2026年一季报简析：净利润同比增长82.94%，短期债务压力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2631891578","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631891578?lang=zh_cn&edition=full","pubTime":"2026-04-30 06:41","pubTimestamp":1777502464,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期翰宇药业发布2026年一季报。截至本报告期末，公司营业总收入2.99亿元，同比下降3.49%，归母净利润1.28亿元，同比上升82.94%。本报告期翰宇药业短期债务压力上升，流动比率达0.43。本次财报公布的各项数据指标表现一般。公司业绩具有周期性。去年的净利率为3.52%，算上全部成本后，公司产品或服务的附加值不高。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000022523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631927536","title":"图解翰宇药业一季报：第一季度单季净利润同比增长82.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631927536","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631927536?lang=zh_cn&edition=full","pubTime":"2026-04-29 04:30","pubTimestamp":1777408225,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业2026年一季报显示，一季度公司主营收入2.99亿元，同比下降3.49%；归母净利润1.28亿元，同比上升82.94%；扣非净利润1.24亿元，同比上升88.91%；负债率77.52%，投资收益4698.33万元，财务费用2617.01万元，毛利率64.9%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900009630.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627238416","title":"翰宇药业（300199）披露控股股东部分股票质押暨解除质押公告，4月15日股价下跌1.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627238416","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627238416?lang=zh_cn&edition=full","pubTime":"2026-04-15 22:10","pubTimestamp":1776262236,"startTime":"0","endTime":"0","summary":"截至2026年4月15日收盘，翰宇药业报收于20.94元，较前一交易日下跌1.27%，最新总市值为184.95亿元。该股当日开盘21.22元，最高21.55元，最低20.66元，成交额达12亿元，换手率为7.63%。近日，翰宇药业披露《关于控股股东、实际控制人办理部分股票质押暨解除质押业务的公告》。三人合计解除质押18,870,000股，占公司总股本2.14%。本次质押用于融资担保，与上市公司生产经营无关。截至公告日，控股股东累计质押股份101,689,600股，占其所持股份比例55.45%，占公司总股本11.51%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500042956.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0070","300199","BK0028","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620244770","title":"翰宇药业（300199）披露2026年第二次临时股东会决议公告，3月17日股价上涨1.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620244770","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620244770?lang=zh_cn&edition=full","pubTime":"2026-03-17 17:06","pubTimestamp":1773738407,"startTime":"0","endTime":"0","summary":"截至2026年3月17日收盘，翰宇药业报收于18.26元，较前一交易日上涨1.16%，最新总市值为161.28亿元。近日，翰宇药业发布《2026年第二次临时股东会决议公告》。公告显示，公司于2026年3月16日召开2026年第二次临时股东会，会议由董事会召集，董事长曾少贵主持，采用现场与网络投票相结合方式举行。出席会议股东共783人，代表股份占公司有表决权股份总数的21.9506%。表决结果显示两项议案均获通过，其中中小股东对第二项议案的支持率为87.0438%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700029043.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","BK0070","BK0028","BK0188","300199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614661008","title":"政旦志远会计所2025年收入破亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2614661008","media":"YCY会计行业观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614661008?lang=zh_cn&edition=full","pubTime":"2026-02-28 00:02","pubTimestamp":1772208120,"startTime":"0","endTime":"0","summary":"最近一个会计年度的收入总额12,123.23万元，审计业务收入为10,599.28万元，证券业务收入为8,421.43万元。2025年度上市公司年报审计收费：4,967万元。截止公告日，政旦志远（深圳）会计师事务所已购买职业责任保险，职业保险累计赔偿限额：10,000万元，并计提职业风险基金。部分会计所2025年业务收入：","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-02-28/doc-inhphuva0535406.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK0188","BK0077","BK0028","300199","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614088226","title":"翰宇药业：公司已通过前瞻性布局产能扩张、持续完善质量体系与全球合规认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2614088226","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614088226?lang=zh_cn&edition=full","pubTime":"2026-02-27 15:48","pubTimestamp":1772178487,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业(300199)02月26日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司跟礼来有直接或间接业务往来吗？翰宇药业回复：尊敬的投资者您好！公司业务合作情况请以公告和公众号等官方信息为准。目前全球 GLP‑1 原料药市场正处于高速增长阶段，随着口服剂型的普及、减重适应症的不断拓展，行业整体市场规模预计将持续快速扩容。公司已通过前瞻性布局产能扩张、持续完善质量体系与全球合规认证，为迎接市场扩容、巩固行业领先地位做好了充足准备。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700021723.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0188","BK0077","BK0239","300199","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614380550","title":"翰宇药业（300199）披露召开2026年第二次临时股东会的通知，2月25日股价上涨2.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614380550","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614380550?lang=zh_cn&edition=full","pubTime":"2026-02-25 22:12","pubTimestamp":1772028740,"startTime":"0","endTime":"0","summary":"截至2026年2月25日收盘，翰宇药业报收于18.7元，较前一交易日上涨2.63%，最新总市值为165.17亿元。该股当日开盘18.23元，最高18.7元，最低18.17元，成交额达3.69亿元，换手率为2.67%。近日，翰宇药业发布《关于召开2026年第二次临时股东会的通知》。公告显示，公司将于2026年3月16日召开2026年第二次临时股东会，会议由公司董事会召集，采取现场投票与网络投票相结合的方式。股权登记日为2026年3月9日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500037934.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","BK0028","BK0188","300199","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614082535","title":"翰宇药业：预计2025年归母净利润扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2614082535","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614082535?lang=zh_cn&edition=full","pubTime":"2026-02-25 20:52","pubTimestamp":1772023954,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业02月25日在投资者关系平台上答复投资者关心的问题。投资者提问：为何公司25年下半年业绩变化如此无常，利润如此低下呢？翰宇药业回复：尊敬的投资者您好，1 月 28 日，公司发布 2025 年度业绩预告，预计全年实现营业收入 9.50 亿元至 9.80 亿元，归母净利润实现扭亏为盈，达到 4000 万元至 5000 万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500036500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613544791","title":"翰宇药业（300199）披露醋酸格拉替雷注射液获美国FDA批准证书，2月24日股价下跌0.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613544791","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613544791?lang=zh_cn&edition=full","pubTime":"2026-02-24 17:32","pubTimestamp":1771925562,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘，翰宇药业报收于18.22元，较前一交易日下跌0.44%，最新总市值为160.93亿元。该股当日开盘18.49元，最高18.49元，最低18.14元，成交额达2.28亿元，换手率为1.67%。近日，深圳翰宇药业股份有限公司收到美国食品药品监管局下发的醋酸格拉替雷注射液新药简略申请批准证书，ANDA号为213382、214022，规格为20mg/mL、40mg/mL。该药品用于治疗复发型多发性硬化，可降低复发频率，延缓疾病进展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400033146.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","BK0188","BK0028","BK0077","300199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610577946","title":"翰宇药业(300199.SZ)：醋酸格拉替雷注射液获得美国FDA批准证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2610577946","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610577946?lang=zh_cn&edition=full","pubTime":"2026-02-12 17:19","pubTimestamp":1770887976,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业(300199.SZ)发布公告，近日，公司收到美国食品药品监管局(以下简称“FDA”)下发的醋酸格拉替雷注射液新药简略申请(以下简称“ANDA”)批准证书。醋酸格拉替雷是一种用于治疗复发型多发性硬化(MS)的免疫调节药物，属于合成多肽类制剂，通过模拟髓鞘碱性蛋白的结构，调节异常的自身免疫反应，从而减少对中枢神经系统髓鞘的攻击。该药可降低复发频率，延缓疾病进展，适用于临床孤立综合征及复发缓解型多发性硬化患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404701.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰宇药业(300199.SZ)：醋酸格拉替雷注射液获得美国FDA批准证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0239","BK0077","300199","BK0028","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606797279","title":"翰宇药业最新公告：2025年预盈4000万元–5000万元GLP-1制剂与原料药业务规模大幅放量","url":"https://stock-news.laohu8.com/highlight/detail?id=2606797279","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606797279?lang=zh_cn&edition=full","pubTime":"2026-01-28 18:39","pubTimestamp":1769596768,"startTime":"0","endTime":"0","summary":"翰宇药业(300199.SZ)公告称，翰宇药业预计2025年归属于上市公司股东的净利润为盈利4000万元–5000万元，上年同期为亏损17365.40万元。报告期内，公司预计归属于上市公司股东的净利润实现扭亏为盈。主要原因在于公司GLP-1制剂与原料药业务规模大幅放量，CRDMO业务落地推进。同时持续加大以创新药HY3003为首的研发投入力度，提高核心产品的竞争力。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800034921.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","300199","BK0070","BK0077","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604135410","title":"中国药企拿下诺和诺德订单？涉1.8亿元GLP-1原料药","url":"https://stock-news.laohu8.com/highlight/detail?id=2604135410","media":"健识局","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604135410?lang=zh_cn&edition=full","pubTime":"2026-01-19 20:28","pubTimestamp":1768825711,"startTime":"0","endTime":"0","summary":"1月16日，翰宇药业发布公告称：公司与一家客户签订了合同，涉及采购金额1.8亿元的GLP-1原料药。翰宇药业作为原料药市场的先行者，无疑是供应链转移的受益者。2023年9月，翰宇药业发布公告称，旗下子公司武汉翰宇与美国某客户签订累计金额3000万美元的GLP-1多肽原料药。翰宇药业借助向“美国客户”销售GLP-1原料药产品的优势，开始在行业里确立供应商的地位。这笔1.8医院的GLP-1原料订单，能否扭转翰宇药业持续亏损的颓势，目前还不好说。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260119205354a43d0d23&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260119205354a43d0d23&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BKVL7J92.USD","BK4585","BK4588","IE00BZ1G4Q59.USD","NVO","BK4007","BK4599","LU1093756325.SGD","300199","LU1093756168.USD","BK4532","LU0154236417.USD","BK4144","BK4590"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1780645042594,"stockEarnings":[{"period":"1week","weight":-0.0612},{"period":"1month","weight":0.1022},{"period":"3month","weight":0.3291},{"period":"6month","weight":0.2095},{"period":"1year","weight":0.5446},{"period":"ytd","weight":0.2771}],"compareEarnings":[{"period":"1week","weight":-0.01},{"period":"1month","weight":-0.0132},{"period":"3month","weight":-0.0161},{"period":"6month","weight":0.0397},{"period":"1year","weight":0.2019},{"period":"ytd","weight":0.0224}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳翰宇药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"98777人(较上一季度减少2.42%)","perCapita":"7543股","listingDate":"2011-04-07","address":"广东省深圳市龙华区观澜高新园区观盛四路7号翰宇创新产业大楼","registeredCapital":"88324万元","survey":" 深圳翰宇药业股份有限公司的主营业务是多肽制剂、原料药、小核酸与CRDMO的研发、销售。公司的主要产品是多肽制剂、原料药、小核酸与CRDMO。","listedPrice":30.19},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰宇药业(300199)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰宇药业(300199)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰宇药业,300199,翰宇药业股票,翰宇药业股票老虎,翰宇药业股票老虎国际,翰宇药业行情,翰宇药业股票行情,翰宇药业股价,翰宇药业股市,翰宇药业股票价格,翰宇药业股票交易,翰宇药业股票购买,翰宇药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰宇药业(300199)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰宇药业(300199)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}